Q4 24 EPS
$2.09
Q4 24 Revenue
$14.89B
vs S&P Since Q4 24
+11.8%
BEATING MARKET
AZN +31.8% vs S&P +20.0%
Full Year 2024 Results
FY 24 EPS
$8.21
FY 24 Revenue
$54.07B
Market Reaction
Did AZN Beat Earnings? Q4 2024 Results
AstraZeneca closed out 2024 with a powerful fourth quarter, posting revenue of $14.89 billion, up 25% at constant exchange rates, as the British drugmaker capped a year in which full-year total revenue climbed 21% at CER to $54.07 billion. Core EPS f… Read more AstraZeneca closed out 2024 with a powerful fourth quarter, posting revenue of $14.89 billion, up 25% at constant exchange rates, as the British drugmaker capped a year in which full-year total revenue climbed 21% at CER to $54.07 billion. Core EPS for the full year rose 19% at CER to $8.21, while Q4 reported EPS came in at $2.09, reflecting the broad momentum that has made AstraZeneca one of the industry's most consistent growth stories. The single most compelling engine behind the numbers was Farxiga, whose $7.72 billion in annual revenue, up 31% at CER, underscored how far the cardiovascular and kidney franchise has extended beyond its diabetes origins. Oncology also punched well above its weight, with Enhertu's combined global sales reaching $3.75 billion as the antibody-drug conjugate continued winning new indications. Looking ahead, management guided for high single-digit total revenue growth and low double-digit core EPS growth in 2025 at CER, and separately moved to deepen its China presence with the acquisition of FibroGen's local subsidiary for roughly $160 million.
Key Takeaways
- • Strong demand growth across Oncology portfolio including Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu
- • Farxiga growth driven by expanding heart failure and CKD indications with SGLT2 class growth
- • Ultomiris neurology expansion and conversion from Soliris
- • New launches including Beyfortus, Truqap, Datroway, and Airsupra
- • Collaboration Revenue surge from Lynparza $600m sales milestone and Beyfortus/Koselugo milestones
- • Tezspire revenue nearly doubled year-over-year on strong biologic-naive patient volume growth
- • Enhertu combined global sales reached $3.75 billion with rapid uptake in HER2-low breast cancer
AZN YoY Financials
Q4 2024 vs Q4 2023, source: SEC Filings
AZN Revenue by Segment
With YoY comparisons, source: SEC Filings
AZN Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also delivered nine positive high value Phase III studies in the year, which coupled with increasing demand for our medicines in all key regions, will help sustain our growth momentum into 2025.”
— Pascal Soriot, Q4 2024 Earnings Press Release
AZN Earnings Trends
AZN vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
AZN EPS Trend
Earnings per share: estimate vs actual
AZN Revenue Trend
Quarterly revenue: estimate vs actual
AZN Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.58 | — | $15.29B | — |
| Q4 25 FY | — | $2.12 | — | $15.50B | +1.26% |
| FY Full Year | $4.59 | $9.16 | +99.72% | $58.74B | +0.33% |
| Q3 25 FY | — | $2.38 | — | $15.19B | — |
| FY Full Year | $4.59 | — | — | — | — |
| Q1 25 | — | $2.49 | — | $13.59B | — |
| Q4 24 FY | — | $2.09 | — | $14.89B | — |
| FY Full Year | — | $8.21 | — | $54.07B | — |